Shawn Ryan — former Navy SEAL, CIA paramilitary officer, and host of the Shawn Ryan Show — has spoken publicly about ibogaine as a treatment for PTSD. His interviews on the subject, some with clinicians involved in the underlying research, have reached audiences that peer-reviewed literature does not. What he describes aligns with what a 2023 Stanford study published in Nature Medicine documented: in 30 special operations veterans, ibogaine produced 88% reductions in PTSD symptoms, 87% reductions in depression, and 81% reductions in anxiety at one month — outcomes that have not been replicated by conventional treatment.
Shawn Ryan is a former Navy SEAL and CIA paramilitary officer who has publicly advocated for ibogaine as a PTSD treatment for veterans. His position draws on a 2023 Stanford study in Nature Medicine finding 88% PTSD symptom reductions in 30 special operations veterans at one month. Ibogaine is not legally available in the United States. Veterans who want access travel to Canada or Mexico.
Who Shawn Ryan Is and How He Reached This Population
Shawn Ryan served in the Navy SEALs and later as a CIA paramilitary officer. He is best known outside those communities as the host of the Shawn Ryan Show — a podcast with tens of millions of downloads, focused primarily on special operations, intelligence, and veteran affairs.
His public engagement with ibogaine began through direct contact with the research and with veterans who had undergone treatment. He has interviewed clinicians, researchers connected to the Stanford study, and veterans who attribute meaningful recovery from PTSD to ibogaine. His framing is not speculative: ibogaine has serious scientific backing, and American veterans cannot legally access it.
That framing is accurate. It is also incomplete, and the parts that tend to be missing from advocacy conversations are the parts that determine whether a specific person should be in a ceremony room at all. The wider public conversation about ibogaine — Ryan, Conor McGregor, Joe Rogan, and others — has surfaced a real and underserved treatment question. What it has not done is communicate the medical specificity that applies to individual candidates.
What the Stanford Research Actually Found
In February 2023, Nature Medicine published a Stanford University study examining ibogaine in 30 male special operations veterans with PTSD, traumatic brain injury, or both. All participants had prior treatment exposure — medication, therapy, or veterans programme participation — and had not achieved adequate resolution.
Special operations veterans are not people who enter things naively. They have been through programmes, been given diagnoses and medications, and many carry well-earned scepticism that anything is going to work. The Stanford study documented what practitioners had been observing for years: ibogaine produces changes in this population that conventional approaches do not. The 88% reduction in PTSD symptom scores at one month is striking not because of the number alone, but because of who that number applies to — people who had already tried everything else.
At one month after a single ibogaine session, the study found:
- 88% reduction in PTSD symptom scores
- 87% reduction in depression symptom scores
- 81% reduction in anxiety symptom scores
- Significant improvements in cognitive function and functional disability ratings
The study did not include a placebo arm. Thirty participants is not a definitive clinical trial. These are genuine methodological limitations, and citing the numbers without those caveats is not honest. But the numbers stand on their own with the caveats included — the direction of the evidence is consistent with what has been observed in smaller studies across different populations over several decades. Shawn Ryan is not extrapolating from a single anomalous finding.
For a closer look at the PTSD-specific research, the ibogaine for PTSD guide covers the mechanism and the broader literature beyond the Stanford paper.
How Ibogaine Acts on a Traumatised Brain
The mechanism matters because it explains why ibogaine produces results in a population where SSRIs, exposure therapy, and standard PTSD protocols have not.
Ibogaine is pharmacologically unusual. It triggers the release of BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) — proteins responsible for neural growth and synaptic repair. It acts as an NMDA receptor antagonist, disrupting entrenched memory consolidation. It has agonist and antagonist activity at multiple opioid receptors, and it inhibits serotonin and dopamine reuptake transporters through mechanisms distinct from standard antidepressants.
For trauma, the relevant combination appears to be elevated neuroplasticity alongside some reduction in defensive activation around traumatic material — creating conditions in which the source content of PTSD becomes more accessible. The cellular mechanics of this are not fully understood. What is documented is the effect size in the population studied.
Ibogaine is metabolised into noribogaine, its primary active metabolite, which remains pharmacologically active for weeks to months after a single session. This sustains an elevated neuroplasticity window — the period in which integration work takes place. The ceremony opens the window. What determines whether the one-month outcomes in the Stanford study hold at six or twelve months is largely what happens during that window.
What Is Changing in Policy and Research
Ibogaine has been Schedule I in the United States since 1970. The scheduling decision was made under political conditions that had nothing to do with the available evidence — and the scheduling ensured the evidence base stayed thin for the next fifty years. The fact that ibogaine research was constrained by scheduling law for more than half a century is a policy failure, not a scientific verdict. The evidence that exists — developed despite those constraints, largely outside the United States — points consistently in the same direction.
That is beginning to change. Texas has committed $50 million to ibogaine clinical trials through the University of Texas Medical Branch, UTHealth Houston, Texas A&M, and Baylor College of Medicine — the largest single government commitment to ibogaine research to date. The Veterans Administration has begun engaging with the literature. Oregon and Colorado have built regulatory frameworks for supervised psychedelic use, though ibogaine is not yet included in either.
None of this changes current access. Veterans seeking ibogaine treatment travel. Canada — where iboga root bark is not listed under the Controlled Drugs and Substances Act — is the nearest legal option for most Americans. Vancouver is 45 minutes north of the Washington State border. Mexico has no restrictions on ibogaine and hosts a number of clinics; medical infrastructure there varies considerably by provider. The relevant questions when comparing access points are about screening rigour and medical staffing, not proximity. See the guide to ibogaine treatment in Canada for what the Canadian legal environment means in practice.
What Veteran Advocacy Does Not Tell You
Shawn Ryan and others who have brought ibogaine to wider veteran audiences are surfacing a genuine and underacknowledged treatment question. The treatment exists, the evidence is real, and the population that needs it has been inadequately served by what conventional medicine has offered. That is a service worth doing.
What advocacy tends not to communicate in detail is the medical specificity that determines whether an individual is a candidate. This matters more in a veteran population than in most.
Ibogaine extends the cardiac QT interval. For most people, this is manageable under proper medical conditions. For someone with undetected QT prolongation, a significant arrhythmia, or undiagnosed structural cardiac issues — all elevated risks in a population with combat injury histories and medication exposures — this mechanism is what has produced deaths in contexts where screening was skipped. Any provider who proceeds without a 12-lead EKG and cardiovascular assessment is not operating safely. This is not a preference. It is the difference between a ceremony and a fatality.
Veterans on antidepressants face a separate hard stop. SSRIs and SNRIs are absolute contraindications for ibogaine — not cautions to be weighed, not relative risks to consider, but hard medical contraindications with no case-by-case exception. The risk of serotonin syndrome is real and potentially fatal. A completed, physician-supervised taper must be confirmed before any ceremony date is set. This typically takes 2–4 weeks, sometimes longer for medications with extended half-lives.
What this means practically: a meaningful number of veterans interested in ibogaine based on Shawn Ryan's interviews are not currently appropriate candidates — not because the treatment is wrong for them, but because their present medication situation or cardiac history requires preparation first. Screening determines which category a specific person is in. That conversation belongs before anything else.
The full list of contraindications is covered in detail in the ibogaine contraindications guide.
Who Is Not an Appropriate Candidate
These are absolute medical contraindications, not risk factors to weigh:
- QT prolongation or significant cardiac arrhythmia — ibogaine extends the QT interval. This is the mechanism behind ibogaine-related cardiac deaths. A 12-lead EKG screens for this before ceremony, not during.
- Current SSRI or SNRI use without a completed supervised taper — serotonin syndrome risk is real and potentially fatal. No exception exists.
- Lithium — absolute contraindication due to cardiac and seizure interaction risk.
- Current methadone use without a supervised transition to a shorter-acting opioid first.
- Severe liver or kidney disease — ibogaine is hepatically metabolised. A liver function panel is required before any ceremony date is confirmed.
- Active psychosis or schizophrenia-spectrum disorder — the ceremony amplifies what is present. Entering in acute psychiatric instability does not produce stability.
- Pregnancy.
Some of these are preparation timelines, not permanent disqualifications. A veteran on SSRIs who completes a supervised taper may be a candidate once that is confirmed. Someone with elevated liver enzymes from alcohol use may qualify once those values normalise. Medical screening determines this — which is why it should precede any financial commitment or travel planning.
Is Ibogaine the Right Path for You?
If you have treatment-resistant PTSD and have encountered ibogaine through Shawn Ryan's interviews or through the Stanford data directly, the evidence supports taking the question seriously. The 88% reduction in PTSD symptoms, 87% in depression, and 81% in anxiety at one month are not numbers produced by a population that responded easily to other things. They are the outcomes in people who had already tried what was available.
Whether you are an appropriate candidate depends on cardiac history, current medications, and where your mental state is right now. That determination happens through the screening and application process, not by reading about the Stanford study.
For more on what the ceremony involves, the ceremony page covers structure, duration, and what the days before and after look like. For specific questions about candidacy, medications, and the intake process, the FAQ covers the most common ones directly. The email address is jake.nylund@gmail.com — every application receives a personal response within 2–3 business days.